EP3618923A1 - Système et procédé de traitement de la myopie - Google Patents

Système et procédé de traitement de la myopie

Info

Publication number
EP3618923A1
EP3618923A1 EP17908615.2A EP17908615A EP3618923A1 EP 3618923 A1 EP3618923 A1 EP 3618923A1 EP 17908615 A EP17908615 A EP 17908615A EP 3618923 A1 EP3618923 A1 EP 3618923A1
Authority
EP
European Patent Office
Prior art keywords
eye tissue
eye
tissue
myopia
pulsed energy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP17908615.2A
Other languages
German (de)
English (en)
Other versions
EP3618923A4 (fr
Inventor
Jeffrey K. LUTTRULL
David B. Chang
Benjamin W. L. Margolis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ojai Retinal Technology LLC
Original Assignee
Ojai Retinal Technology LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/583,096 external-priority patent/US10953241B2/en
Priority claimed from US15/629,002 external-priority patent/US10278863B2/en
Application filed by Ojai Retinal Technology LLC filed Critical Ojai Retinal Technology LLC
Publication of EP3618923A1 publication Critical patent/EP3618923A1/fr
Publication of EP3618923A4 publication Critical patent/EP3618923A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/0622—Optical stimulation for exciting neural tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/008—Methods or devices for eye surgery using laser
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/0625—Warming the body, e.g. hyperthermia treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/067—Radiation therapy using light using laser light
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
    • A61F2007/0001—Body part
    • A61F2007/0002—Head or parts thereof
    • A61F2007/0004—Eyes or part of the face surrounding the eyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/008—Methods or devices for eye surgery using laser
    • A61F2009/00861—Methods or devices for eye surgery using laser adapted for treatment at a particular location
    • A61F2009/00863—Retina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0635—Radiation therapy using light characterised by the body area to be irradiated
    • A61N2005/0642—Irradiating part of the body at a certain distance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0659—Radiation therapy using light characterised by the wavelength of light used infrared

Definitions

  • Myopia is epidemic by usual medical definitions, affecting as many as 50% of adults, with increases in incidents in school-aged children in recent generations by 200% or more. This rapid increase and prevalence has been attributed to improved educational opportunities with increased reading time, as well as increased use of electronic devices and media.
  • the causes of typical myopia appear to be genetic and environment. Higher education and greater time spent doing close work and reading are known to be risk factors for myopia.
  • the stimulus for near work causing myopia suggests that this influences, possibly in part via accommodation of the crystalline lens, neurologic and/or chemical mediators of eye growth to increase the axial length of the eye. Evidence for this phenomenon is that paralyzation of accommodation with topical atropine in children is able to reduce the degree and incidence of acquired myopia.
  • the pulsed energy may be applied to a plurality of eye tissue areas, wherein adjacent eye tissue areas are separated by at least a predetermined distance to avoid thermal tissue damage.
  • the pulsed energy may be applied to a first eye tissue area and, after a predetermined period of time within a single treatment session, the pulsed energy is reapplied to the first eye tissue area.
  • the pulsed energy is applied to a second eye tissue area.
  • FIGURE 1 is a graph illustrating an average power of a laser source having a wavelength compared to a source radius and pulse train duration of the laser;
  • FIGURE 9 is a top view of an optical scanning mechanism, used in accordance with the present invention.
  • FIGURE 1 0 is a partially exploded view of the optical scanning mechanism of FIG. 9, illustrating various component parts thereof;
  • FIGURE 1 1 is a diagrammatic view illustrating controlled offset of exposure of an exemplary geometric pattern grid of laser spots to treat the eye tissue, in accordance with the present invention
  • SDM subthreshold diode micropulsed laser
  • the subthreshold retinal photocoagulation is defined as retinal laser applications biomicroscopically invisible at the time of treatment.
  • Truste subthreshold photocoagulation, as a result of the present invention, is invisible and includes laser treatment non-discernible by any other known means such as FFA, FAF, or even SD-OCT.
  • Truste subthreshold photocoagulation is therefore defined as a laser treatment which produces absolutely no retinal damage detectable by any means at the time of treatment or any time thereafter by known means of detection.
  • “true subthreshold” is the absence of lesions and other tissue damage and destruction.
  • the invention may be more accurately referred to as photostimulation than photocoagulation due to the absence of typical photocoagulation damage.
  • the exposure envelope duration is a duration of time where the micropulsed laser beam would be exposed to the same spot or location of the retina, although the actual time of exposure of the tissue to the laser is much less as the laser light pulse is less than a millisecond in duration, and typically between 50
  • Invisible phototherapy or true subthreshold photocoagulation in accordance with the present invention can be performed at various laser light wavelengths, such as from a range of 532 nm to 1 300 nm. Use of a different wavelength can impact the preferred intensity or power of the laser light beam and the exposure envelope duration in order that the retinal tissue is not damaged, yet therapeutic effect is achieved.
  • HSPs heat shock proteins
  • SDM produces prompt clinical effects, such as rapid and significant improvement in retinal electrophysiology, visual acuity, contrast visual acuity and improved macular sensitivity measured by
  • SDM treatment of patients suffering from age-related macular degeneration can slow the progress or even stop the progression of AMD.
  • Most of the patients have seen significant improvement in dynamic functional logMAR mesoptic visual acuity and mesoptic contrast visual acuity after the SDM treatment. It is believed that SDM works by targeting, preserving, and "normalizing" (moving toward normal) function of the retinal pigment epithelium (RPE).
  • RPE retinal pigment epithelium
  • FIGURES 1 and 2 illustrate graphs showing the average power in watts as compared to the laser source radius (between 0.1 cm and 0.4 cm) and pulse train duration (between 0.1 and 0.6 seconds).
  • FIG. 1 shows a wavelength of 880 nm
  • FIG. 2 has a wavelength of 1 000 nm. It can be seen in these figures that the required power decreases monotonically as the radius of the source decreases, as the total train duration increases, and as the
  • the minimum power value is 0.77 watts with a laser source radius of 1 mm and a total pulse train duration of 600 milliseconds, and a maximum power value of 73.6 watts when the laser source radius is 4 mm and the total pulse duration is 1 00 milliseconds.
  • the average temperature rise of the target tissue over any six-minute period is 1 ° C or less.
  • the temperature decay time is 1 07 seconds when the source diameter is 4 mm.
  • the temperature decay time is 1 8 seconds when the source diameter is 1 mm and 1 36 seconds when the source diameter is 4 mm.
  • the laser light beam 42 is passed through a collimator lens 44 and then through a mask 46.
  • the mask 46 comprises a diffraction grating.
  • the mask/diffraction grating 46 produces a geometric object, or more typically a geometric pattern of simultaneously produced multiple laser spots or other geometric objects. This is represented by the multiple laser light beams labeled with reference number 48.
  • manufacturing can be used to create the simultaneous geometric pattern of spots or other objects.
  • the absorption coefficient in the RPE's melanin can be higher, and therefore the laser power can be lower.
  • the power can be lowered by a factor of 4 for the invention to be effective. Accordingly, there can be as few as a single laser spot or up to approximately 400 laser spots when using the 577 nm wavelength laser light, while still not harming or damaging the eye.
  • the present invention can use a multitude of simultaneously generated therapeutic light beams or spots, such as numbering in the dozens or even hundreds, as the parameters and methodology of the present invention create therapeutically effective yet non-destructive and non-permanently damaging treatment, allowing the laser light spots to be applied to any portion of the retina, including the fovea, whereas conventional techniques are not able to use a large number of simultaneous laser spots, and are often restricted to only one treatment laser beam, in order to avoid accidental exposure of sensitive areas of the retina, such as the fovea, as these will be damaged from the exposure to conventional laser beam methodologies, which could cause loss of eyesight and other complications.
  • FIGURE 5 illustrates diagrammatically a system which couples multiple light sources into the pattern-generating optical subassembly described above.
  • this system 30' is similar to the system 30 described in FIG. 3 above.
  • the primary differences between the alternate system 30' and the earlier described system 30 is the inclusion of a plurality of laser consoles 32 , the outputs of which are each fed into a fiber coupler 54.
  • the fiber coupler produces a single output that is passed into the laser projector optics 34 as described in the earlier system.
  • the coupling of the plurality of laser consoles 32 into a single optical fiber is achieved with a fiber coupler 54 as is known in the art.
  • Other known mechanisms for combining multiple light sources are available and may be used to replace the fiber coupler described herein.
  • the geometric pattern of simultaneous laser spots is sequentially offset so as to achieve confluent and complete treatment of the retinal surface.
  • a segment of the retina can be treated in accordance with the present invention, more ideally the entire retina will be treated within one treatment session. This is done in a time- saving manner by placing a plurality of spots over the entire ocular fundus at once. This pattern of simultaneous spots is scanned, shifted, or redirected as an entire array sequentially, so as to cover the entire retina in a single treatment session.
  • the total time in accordance with the embodiments described above to treat a given area, or more particularly the locations on the retina which are being exposed to the laser spots is between 200 milliseconds and 500 milliseconds on average.
  • the thermal relaxation time is required so as not to overheat the cells within that location or spot and so as to prevent the cells from being damaged or
  • the lower curve is for panmacular treatment and the upper curve is for panretinal treatment. This would be for a laser light beam having a micropulse time of 50 microseconds, a period of 2 milliseconds period of time between pulses, and duration of train on a spot of 300
  • Fixation software could monitor the displayed image of the ocular fundus. Prior to initiating treatment of a fundus landmark, such as the optic nerve, or any part or feature of either eye of the patient (assuming orthophoria), could be marked by the operator on the display screen. Treatment could be initiated and the software would monitor the fundus image or any other image- registered to any part of either eye of the patient (assuming orthophoria) to ensure adequate fixation. A break in fixation would automatically interrupt treatment. A break in fixation could be detected optically; or by interruption of low energy infrared beams projected parallel to and at the outer margins of the treatment beam by the edge of the pupil. Treatment would automatically resume toward completion as soon as fixation was established. At the establishment of a fundus landmark, such as the optic nerve, or any part or feature of either eye of the patient (assuming orthophoria), could be marked by the operator on the display screen. Treatment could be initiated and the software would monitor the fundus image or any other image- registered to any part of either eye of the patient (assuming orthophoria) to ensure adequate
  • the laser could be projected via a wide field non-contact lens to the ocular fundus. Customized direction of the laser fields or particular target or area of the ocular fundus other than the central area could be accomplished by an operator joy stick or eccentric patient gaze.
  • the laser delivery optics could be coupled coaxially to a wide field non-contact digital ocular fundus viewing system.
  • the image of the ocular fundus produced could be displayed on a video monitor visible to the laser operator. Maintenance of a clear and focused image of the ocular fundus could be facilitated by a joy stick on the camera assembly manually directed by the operator. Alternatively, addition of a target registration and tracking system to the camera software would result in a completely automated treatment system.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Vascular Medicine (AREA)
  • Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Radiation-Therapy Devices (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Prostheses (AREA)
  • Laser Surgery Devices (AREA)

Abstract

Un procédé de prévention ou de traitement de la myopie comprend l'application d'une énergie pulsée, telle qu'un faisceau laser pulsé, au tissu d'un oeil présentant une myopie ou un risque de myopie. La source d'énergie pulsée présente des paramètres d'énergie comprenant la longueur d'onde ou la fréquence, le rapport cyclique et la durée du train d'impulsions, qui sont sélectionnés de façon à élever une température de tissu oculaire jusqu'à onze degrés Celsius pour obtenir un effet thérapeutique ou prophylactique, tel que la stimulation de l'activation de la protéine de choc thermique dans le tissu oculaire. L'élévation de température moyenne du tissu oculaire pendant plusieurs minutes est maintenue à un niveau prédéterminé ou en-dessous de façon à ne pas endommager de façon permanente le tissu oculaire.
EP17908615.2A 2017-05-01 2017-12-05 Système et procédé de traitement de la myopie Withdrawn EP3618923A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15/583,096 US10953241B2 (en) 2012-05-25 2017-05-01 Process for providing protective therapy for biological tissues or fluids
US15/629,002 US10278863B2 (en) 2016-03-21 2017-06-21 System and process for treatment of myopia
PCT/US2017/064708 WO2018203930A1 (fr) 2017-05-01 2017-12-05 Système et procédé de traitement de la myopie

Publications (2)

Publication Number Publication Date
EP3618923A1 true EP3618923A1 (fr) 2020-03-11
EP3618923A4 EP3618923A4 (fr) 2020-03-11

Family

ID=64016725

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17908615.2A Withdrawn EP3618923A4 (fr) 2017-05-01 2017-12-05 Système et procédé de traitement de la myopie

Country Status (8)

Country Link
EP (1) EP3618923A4 (fr)
JP (2) JP2020518317A (fr)
CN (1) CN110582238A (fr)
AU (1) AU2017412681B2 (fr)
BR (1) BR112019023061A2 (fr)
CA (1) CA3058891A1 (fr)
SG (1) SG11201909214YA (fr)
WO (1) WO2018203930A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10709608B2 (en) 2016-03-21 2020-07-14 Ojai Retinal Technology, Llc System and process for prevention of myopia
JP2022515378A (ja) * 2018-12-21 2022-02-18 エシロール・アンテルナシオナル 視力関連パラメータの経時的な進展を予測するためのモデルを構築するための方法及び装置
WO2020251609A1 (fr) * 2019-06-13 2020-12-17 Ojai Retinal Technology, Llc Système et procédé de prévention de la myopie
CN112386806A (zh) * 2020-10-10 2021-02-23 深圳敬中堂科技有限公司 一种矫治视蛋白基因相关视觉疾病的光源组合及应用
CN113244045A (zh) * 2021-07-15 2021-08-13 中山大学中山眼科中心 一种高效视力恢复方法及其设备

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090100A (en) * 1992-10-01 2000-07-18 Chiron Technolas Gmbh Ophthalmologische Systeme Excimer laser system for correction of vision with reduced thermal effects
US6129722A (en) * 1999-03-10 2000-10-10 Ruiz; Luis Antonio Interactive corrective eye surgery system with topography and laser system interface
US7503655B2 (en) * 2003-11-19 2009-03-17 Vision Crc Limited Methods and apparatuses for altering relative curvature of field and positions of peripheral, off-axis focal positions
CN2817788Y (zh) * 2005-07-19 2006-09-20 冯丹藜 自动变频激光弱视治疗仪
US20100049180A1 (en) * 2007-10-19 2010-02-25 Lockheed Martin Corporation System and method for conditioning animal tissue using laser light
US9403029B2 (en) * 2007-07-18 2016-08-02 Visualase, Inc. Systems and methods for thermal therapy
US8141557B2 (en) * 2008-10-22 2012-03-27 Peyman Gholam A Method of oscillatory thermotherapy of biological tissue
WO2011084863A2 (fr) * 2010-01-07 2011-07-14 Cheetah Omni, Llc Lasers à fibre, et sources de lumière dans l'infrarouge moyen, dans des procédés et systèmes pour le traitement et la spectroscopie sélective de tissus biologiques
CN102038596B (zh) * 2011-01-28 2013-01-09 中山大学中山眼科中心 一种可调控刺激光源的视觉训练仪
US20130110095A1 (en) * 2011-10-26 2013-05-02 Brian S. Boxer Wachler Method of correcting vision problems using only a photodisruption laser
US9427602B2 (en) * 2012-05-25 2016-08-30 Ojai Retinal Technology, Llc Pulsating electromagnetic and ultrasound therapy for stimulating targeted heat shock proteins and facilitating protein repair
US10531908B2 (en) * 2012-05-25 2020-01-14 Ojai Retinal Technology, Llc Method for heat treating biological tissues using pulsed energy sources
US10278863B2 (en) * 2016-03-21 2019-05-07 Ojai Retinal Technology, Llc System and process for treatment of myopia
EP2914193B1 (fr) * 2012-11-01 2021-07-28 Seminex Corporation Traitements de la peau au laser à intensité variable
BR112016000177A2 (pt) * 2013-07-11 2017-12-12 Novartis Ag usos de um antagonista do vegf no tratamento de doenças neovasculares coriorretinianas e de permeabilidade em pacientes pediátricos, seringa pré-cheia, kit e formulação de liberação lenta
BR112017016288A2 (pt) * 2015-01-28 2018-03-27 Ojai Retinal Technology, Llc método para estimular ativação de proteína de choque térmico em tecido
ES2905773T3 (es) * 2015-10-23 2022-04-12 Ojai Retinal Tech Llc Sistema de fototerapia de retina

Also Published As

Publication number Publication date
JP2022184907A (ja) 2022-12-13
AU2017412681A1 (en) 2019-10-31
WO2018203930A1 (fr) 2018-11-08
EP3618923A4 (fr) 2020-03-11
JP2020518317A (ja) 2020-06-25
AU2017412681B2 (en) 2019-11-14
BR112019023061A2 (pt) 2020-06-09
SG11201909214YA (en) 2019-11-28
CN110582238A (zh) 2019-12-17
CA3058891A1 (fr) 2018-11-08

Similar Documents

Publication Publication Date Title
US10709607B2 (en) System and process for treatment of myopia
US10278865B2 (en) Process for neuroprotective therapy for glaucoma
US10285859B2 (en) System for performing retina photostimulation
AU2017412681B2 (en) System and process for treatment of myopia
AU2021215167B2 (en) System and process for retina phototherapy
JP2018531051A6 (ja) 網膜光線療法のためのシステムとプロセス
US10709608B2 (en) System and process for prevention of myopia
EP3451983B1 (fr) Système pour une thérapie neuroprotectrice pour le glaucome
WO2020251609A1 (fr) Système et procédé de prévention de la myopie

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20191111

A4 Supplementary search report drawn up and despatched

Effective date: 20200102

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20200801